Published on Mon Jul 19 2021

Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants

MISHRA, B. K., Bhattacharya, D., Kshatri, J. S., Pati, S.
In India, by 30th June, 2021, not less than 30 million people were infected with COVID-19 and 0.39 million people reported to have lost their life to the disease. Conflicting reports on the persistence of antibody levels in individuals recovered from CO VID-19 infection, suggest that the immunity may not be lasting for long.
43
203
578
Abstract

Conflicting reports on the persistence of antibody levels in individuals recovered from COVID-19 infection, suggest that the immunity against COVID-19 may not be lasting for long. In India, by 30th June, 2021, not less than 30 million people were infected with COVID-19 and 0.39 million people were reported to have lost their life to the disease in India. I the current study we followed up with a subsample of our previous sero-survey participants to assess whether natural immunity against SARS-CoV-2 was associated with a reduced risk of re-infection. We conducted telephonic interview of a total of 3038 participants, out of which 2238 participants responded and 5 participants were found to be not alive, as conveyed by their close relatives. There was a non-response rate of 26.1%. Out of the 2238 participants, 1170 were sero-positive and 1068 were sero-negative for antibody against COVID-19. Our survey found that only 3 individuals in the sero-positive group got infected with COVID-19 whereas 127 individuals reported contracting the infection the sero-negative group. Interestingly, from the 127 sero-negative individuals who later contracted COVID-19 infection, 30 needed hospitalization, out of which 12 were on oxygen therapy, four in ICU and one was on ventilator. At the other hand, from the 3 sero-positives re-infected with COVID-19, one had hospitalization, but didnnot require oxygen support or critical care. These findings reinforce the strong plausibility that development of antibody following natural infection not only protects against re-infection by the virus to a great extent, but also safeguards against progression to severe COVID-19 disease.

Hooman MD PhDShocking! Natural immunity from a prior COVID-19 infection protects against subsequent infection? Wish @CDC @US_FDA understood Y COVID-recovered and already immune Americans should not be mandated or coerced into getting vaccinated! @TuckerCarlson https://www.medrxiv.org/content/10.1101/2021.07.19.21260302v1
Wed Jul 21 2021 at 12:33:14 AM
130
336
Basiukiewicz, Paweł Stanisław, lekarz3 osoby sposrod 1170 seropozytywnych miały reinfekcję. 127 osób spośród 1068 seronegatywnych rozwinęło C19. @OrdoMedicus @PiotrWitczak_ @mikolaj_kam Wnioski: naturalna odporność istotnie redukuje ryzyko C19. https://www.medrxiv.org/content/10.1101/2021.07.19.21260302v1
Mon Jul 19 2021 at 4:50:35 PM
47
197
medRxivNatural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants https://medrxiv.org/cgi/content/short/2021.07.19.21260302v1 #medRxiv
Mon Jul 19 2021 at 4:39:57 PM
8
7
Joel Kahn MD, FACCNatural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants | medRxiv #covid19 https://www.medrxiv.org/content/10.1101/2021.07.19.21260302v1
Wed Jul 21 2021 at 12:53:16 AM
3
7
₿irηα ✨"Estos hallazgos refuerzan la fuerte plausibilidad de que el desarrollo de ANTICUERPOS tras la INECCION NATURAL no sólo protege contra la reinfección por el virus en gran medida, sino que también salvaguarda contra la progresión a la enfermedad grave" https://www.medrxiv.org/content/10.1101/2021.07.19.21260302v1
Tue Jul 27 2021 at 1:34:11 PM
5
2
Sudarshan Chate@RinoRooter Natural immunity against COVID-19 significantly reduces the risk of reinfection. https://www.medrxiv.org/content/10.1101/2021.07.19.21260302v1
Tue Jul 20 2021 at 7:07:12 PM
2
4
Fri Jun 11 2021public and global health
Breakthrough infection with SARS-CoV-2 and its predictors among healthcare workers in a medical college and hospital complex in Delhi, India
The study objective was to determine the breakthrough infection rate of Covid-19 (SARS-CoV-2) infection in those vaccinated with either BBV152 or AZD1222 (ChAdOx1-S) vaccine among healthcare workers (HCWs) The study was conducted at a medical college and hospital complex in Delhi, India through telephonic interviews.
5
221
458
Wed Aug 12 2020public and global health
High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England
We investigated six London care homes experiencing a COVID-19 outbreak. We found very high rates of SARS-CoV-2 infection among residents and staff. Here we report follow-up serological analysis in these care homes five weeks later.
1
3
2
Sat Apr 24 2021epidemiology
Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
Worldwide shortage of vaccination against SARS-CoV-2 infection while the pandemic is still uncontrolled leads many states to the dilemma whether or not to vaccinate previously infected persons. Understanding the level of protection of previous infection compared to that of vaccination is critical for policy making.
140
712
2,136
Tue Apr 20 2021epidemiology
The risk of symptomatic reinfection during the second COVID-19 wave in individuals previously exposed to SARS-CoV-2
To what extent infection with SARS-CoV-2 protects against subsequent reinfection is still unclear. We analyzed surveillance records of COVID-19 cases identified between June 2020 and January 2021 in five Italian municipalities. We compared the risk of observing symptomatic infections in two mutually exclusive groups.
2
0
0
Thu Jul 22 2021public and global health
Effectiveness of Covishield vaccine in preventing Covid-19 -- A test-negative case-control study
Study aimed at assessing the vaccine effectiveness (VE) of Covishield. VE of one dose and of two doses, in providing protection against Covid-19 was 49% (95% CI: 17%-68%) and 54% (27%-71%), respectively.
2
0
1
Fri Apr 30 2021infectious diseases
SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands
Only a few studies have assessed the long-term duration of the humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) The seropositive rate in the convalescent individuals was above 95 % at all sampling time points for both assays.
4
0
0